Scientists create off-the-shelf T cell cancer therapy from cord blood The new highly scalable therapy successfully slowed tumor growth in mouse models of solid tumors. Written byAllison Whitten, PhD

Scientists create off-the-shelf T cell cancer therapy from cord blood The new highly scalable therapy successfully slowed tumor growth in mouse models of solid tumors. Written byAllison Whitten, PhD https://www.drugdiscoverynews.com/scientists-create-off-the-shelf-t-cell-cancer-therapy-from-cord-blood-17543 T cell receptor (TCR) therapy has a major advantage over the more widely known CAR T cell therapy: it goes beyond the cell’s surface to target tumor proteins that lie inside a cell. This makes it a particularly enticing approach for solid tumors where most of the tumor proteins remain on the inside. Yet, TCR therapy falls prey to the same drawbacks as CAR T therapy — namely the fact that personalized treatments made from each individual’s cells can take weeks to engineer, and off-the-shelf approaches from healthy donors can lead to graft-versus-host disease (GvHD).